Leveraged and Inverse ETF Do’s and Mostly Don’ts


Image Credit: Ross Edwin Thompson (Flickr)


Leveraged and Inverse ETFs Contain Extra Costs for Buy-and-Hold Investors

Exchange traded funds are a popular way to invest to gain exposure to an index or an industry sector. If you’re bullish on a sector, they take the work out of selecting individual stocks within that sector. Instead, an ETF allows you to be exposed to many stocks and earn the mixed return of its holdings (less mgmt. fee). This is a valid, and for some, prudent way to invest. It would seem to stand to reason then, with the market’s recent performance, that if you think the equitiies may be weak for a long period that you could invest in an inverse ETF, or even a 2x or 3x inverse. However, it isn’t that easy. There is great danger in these so-called “geared ETFs.” Traders should fully understand this danger so they don’t get caught.

Leveraged or geared ETFs are not invested the same way an index mimicking 1x ETF is. This difference limits their usefulness; they can serve effectively as a hedging tool short term but are likely to fail as a long-term investment play.

Background

The underlying financial tools in a leveraged or inverse ETF are reworked each day to deliver a set positive or negative multiple of the performance of an index. Individually their objective may be to attain the goal over a given time period, such as one day or one month. The most common of the currently listed geared ETFs, leverage factors are 1.5x, 2x, and 3x and inverse factors are -0.5x, -1x, -2x and -3x.

The vast majority of geared ETFs reset their exposure factors each day. This means that the stated leverage or inverse objective they aim for is within a single trading day, generally measured from the close of trading on one day to the close of trading on the next day.

The objective of a geared ETF with a daily reset is to provide that degree of leveraged or inverse exposure for that single period – not over longer (or even shorter) periods. (Similarly, a geared ETP with a monthly objective is designed to provide that leveraged or inverse exposure for a specified monthly period.)

Holding a geared ETF for a period that is shorter or longer than its objective can lead to performance that may deviate significantly from the daily objective. In other words, if you are invested in a 2x inverse S&P 500 ETF, and the benchmark falls 1% in 24 hours, the security should provide you with 2% in return. However if you hold the inverse leveraged ETF for two months and the S&P 500 average decline is 1%, you may have several percentage points eroded from your account assets. I’ll explain below. The investment product is not designed to provide twice the positive or inverse return of the index over longer periods.

Another example is an inverse ETF that seeks to deliver negative 1x the performance of the Nasdaq 100 Index. This ETF aims to deliver a return that is exactly the opposite of what the index returns (whether positive or negative) on a given day. If the Nasdaq 100 closes up 1.5 percent, the inverse ETF would aim to return a loss of 1.5 percent. If the index closes down 2 percent, the ETF should return a gain of 2 percent.

Why Don’t they Function Longer Term?

To achieve their expected returns, leveraged and inverse ETFs employ a range of investment strategies, including swaps, futures, and other derivatives in addition to possible long or short positions in securities.

Since geared ETFs are only designed to accomplish the stated leveraged or inverse objective on a daily basis, they don’t orchestrate their underlying financial instruments to accomplish anything different than that objective. It simply isn’t their goal. In fact, returns often differ significantly from the performance (or inverse of the performance) of their pegged benchmark over an extension beyond the stated period of time. This makes these products risky if they are held medium or long term, especially in volatile markets. While these ETFs can be held for periods that don’t align with their stated objective, generally, the position should be monitored closely and used by investors who understand what the products are designed for and how they incur costs to the longer-term holder – that performance is warped over extended periods.

The fund manager incurs a large daily cost by resetting the underlying instruments, far greater than a straight 1x ETF. Also, most of the underlying instruments incur futures decay as they move closer to their expiration date. Over one day this decay is accounted for in the daily mix, over a longer time period it is felt by the investor.

Things to Consider

Before committing money to any of these ETFs, clearly understand the specific leveraged or inverse ETF before investing in it. Be sure about your own purpose in committing money. Could the ETF accomplish or undermine your goal? Read the prospectus, and understand the objectives, risks, and costs.

When Might You Use a Geared ETF

Most of these ETFs are created to be used to hedge a portfolio or trading position overnight. Trading desks, institutional managers, and savvy retail investors with overnight positions may wish to protect against a large change in portfolio value while they are sleeping or through  weekend.

For example: If a trading desk is long $600,000 in stocks that would be expected to roughly track the Russell 2000, before the close they may protect the position from any big moves overnight by committing $200,000 to a 3x ETF of the index.  

Take-Away

Leveraged and inverse ETFs are designed as very short-term hedging and risk management tools. Investors that are considering a strategy to implement either short ETFs or leveraged should read the prospectus and understand the particular ETF thoroughly. Review the performance over a year versus the expected index.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Will the SEC Double Down on Triple Leveraged ETFs?



Index Funds Still May Fall Apart over Time




Is the Index Bubble Michael Burry Warned About Still Looming?



Did the Stock Market Already Overshoot to the Downside in 2022?

Sources

https://www.sec.gov/investor/pubs/leveragedetfs-alert.htm#:~:text=As%20discussed%20above%2C%20because%20leveraged,the%20index%20showed%20a%20gain.

https://www.finra.org/investors/insights/lowdown-leveraged-and-inverse-exchange-traded-products

 

Stay up to date. Follow us:

 

Cumulus Media (CMLS) – A Sanguine Outlook

Thursday, May 05, 2022

Cumulus Media (CMLS)
A Sanguine Outlook

Cumulus Media (NASDAQ: CMLS) is an audio-first media company delivering premium content to over a quarter billion people every month — wherever and whenever they want it. Cumulus Media engages listeners with high-quality local programming through 406 owned-and-operated radio stations across 86 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, CNN, the AP, the Academy of Country Music Awards, and many other world-class partners across more than 9,500 affiliated stations through Westwood One, the largest audio network in America; and inspires listeners through the Cumulus Podcast Network, its rapidly growing network of original podcasts that are smart, entertaining and thought-provoking. Cumulus Media provides advertisers with personal connections, local impact and national reach through broadcast and on-demand digital, mobile, social, and voice-activated platforms, as well as integrated digital marketing services, powerful influencers, full-service audio solutions, industry-leading research and insights, and live event experiences. Cumulus Media is the only audio media company to provide marketers with local and national advertising performance guarantees. For more information visit www.cumulusmedia.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A solid quarter. Q1 revenues increased a strong 15% to $232.0 million, above our $227.2 million estimate. Adj. EBITDA was $31.2 million, above our $22.2 million estimate.  The Revenues and Adj. EBITDA results benefited from a $5 million in pull forward revenues and adj. EBITDA as a results of the cancelled Wynbet contract. Notably, the company would have beat our Adj. EBITDA estimate, without the adjustment.

Tweaking 2022 estimates upward. We are flowing through a portion of the Q1 upside to our full year 2022 estimates. We are raising our full year 2022 adj. EBIDA estimate from $173.7 million to $175.1 million. At this time, we are maintaining our full year 2023 estimates. …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Solid 1Q22 Sets the Table for 2022

Thursday, May 05, 2022

Great Lakes Dredge & Dock (GLDD)
Solid 1Q22 Sets the Table for 2022

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Operating Results. Revenue of $194.4 million exceed our $176 million estimate and consensus $170 million, partly due to the pull forward of certain business. Margin was a little lighter than projections due to dry dockings and weather issues that restricted work. Nonetheless, adjusted EBITDA for the quarter was $29.7 million versus our $32.7 million estimate. EPS for the quarter was $0.17 compared to our estimate of $0.18.

Favorable Environment. The operating environment remains favorable. The Omnibus Appropriations Bill for fiscal year 2022 included funding for the U.S. Army Corps of Engineers totaling $8.3 billion for fiscal year 2022, an increase of $548 million above the fiscal year 2021 level and an increase of $1.6 billion above the President’s original budget request….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Tokens.com Corp. (SMURF) – Beefing Up the P2E Segment

Thursday, May 05, 2022

Tokens.com Corp. (SMURF)
Beefing Up the P2E Segment

Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Adding More Assets. Tokens.com announced that the Company subsidiary, Hulk Labs, has acquired play-to-earn gaming assets in two platforms, Arcade Land and BitBrawl. Hulk Labs acquired land parcels in Arcade Land and avatar NFTs. The amounts invested in each platform were not disclosed.

Arcade Land Overview. Arcade Land is a Metaverse land-based world that focuses on gaming and play-to-earn. The world holds 10,000 unique plots where NFT holders can build out their parcel and allow other holders to visit, hangout, and play games. These holders can also build stores, place advertising, and sell items, in additional to the land holding yield earning potential, depending on the size, similar to Decentraland….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – First Look at 1Q22

Thursday, May 05, 2022

CoreCivic, Inc. (CXW)
First Look at 1Q22

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Miss. CoreCivic reported first quarter results after the market closed yesterday. Revenue came in at $453 million, compared to $454.7 million in the same period last year. Consensus was $465 million. The Company reported adjusted net income of $17.4 million, or $0.14 per share, compared to $29.3 million, or $0.24 per share last year. Consensus EPS net income was $23.1 million, or $0.19 per share. We had projected revenue of $473 million and EPS of $0.18.

What Drove the Miss? Headwinds include a challenging labor market, especially for nurses, disruption from the commencement of the La Palma contract in Arizona, and a drop in federal detainees, partially offset by higher populations at the state level….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Alvopetro Announces April 2022 Sales Volumes and Q1 2022 Results Webcast



Alvopetro Announces April 2022 Sales Volumes and Q1 2022 Results Webcast

Research, News, and Market Data on Alvopetro Energy

CALGARY, AB, May 5, 2022 /CNW/ – Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) announces April sales volumes of 2,494 boepd, including natural gas sales of 14.3 MMcfpd and associated natural gas liquids sales from condensate of 107 bopd, based on field estimates. 

Upcoming Q1 2022 results webcast

Alvopetro anticipates announcing Q1 2022 results on May 12, 2022 after markets close and will host a live webcast to discuss the results at 8:00 am Mountain time on May 13, 2022. Details for joining the event are as follows:

Date: May 13, 2022

Time: 8:00 AM Mountain/10:00 AM Eastern

Link: https://us06web.zoom.us/j/84318417369

Dial-in Numbers: https://us06web.zoom.us/u/kckYUds2mG

Webinar ID: 843 1841 7369

 

The webcast will include a question-and-answer period. Online participants will be able to ask questions through the Zoom portal. Dial-in participants can email questions directly to socialmedia@alvopetro.com.

Corporate Presentation

Alvopetro’s updated corporate presentation is available on our website at:
http://www.alvopetro.com/corporate-presentation

Social Media

Follow Alvopetro on our social media channels at the following links:

Twitter – https://twitter.com/AlvopetroEnergy
Instagram – https://www.instagram.com/alvopetro/
LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltd
YouTube: https://www.youtube.com/channel/UCgDn_igrQgdlj-maR6fWB0w

Alvopetro Energy Ltd.’s vision is to become a leading
independent upstream and midstream operator in Brazil. Our strategy is to unlock
the on-shore natural gas potential in the state of Bahia in Brazil,
building off the development of our Caburé natural gas field and our strategic
midstream infrastructure.

Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this news release.

All amounts contained in
this new release are in United States dollars, unless otherwise stated and all
tabular amounts are in thousands of United States dollars, except as otherwise
noted.

Abbreviations: 

boepd

=

barrels of oil equivalent (“boe”) per day

bopd

=

barrels of oil and/or natural gas liquids (condensate) per day

MMcf

=

million cubic feet

MMcfpd

=

million cubic feet per day

 

BOE Disclosure. The term barrels of oil
equivalent (“boe”) may be misleading, particularly if used in isolation.
A boe conversion ratio of six thousand cubic feet per barrel (6Mcf/bbl) of
natural gas to barrels of oil equivalence is based on an energy equivalency
conversion method primarily applicable at the burner tip and does not represent
a value equivalency at the wellhead. All boe conversions in this news release
are derived from converting gas to oil in the ratio mix of six thousand cubic
feet of gas to one barrel of oil.

SOURCE Alvopetro Energy Ltd.

For further information: Corey C. Ruttan, President, Chief Executive Officer and Director, or Alison Howard, Chief Financial Officer, Phone: 587.794.4224, Email: info@alvopetro.com,
www.alvopetro.com, (TSX-V: ALV) (OTCQX: ALVOF)

Release – Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022


Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

CARLSBAD, Calif.–()–Lineage Cell
Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2022 financial and operating results on Thursday, May 12, 2022, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2022, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2022 financial and operating results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 20, 2022, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 1875641.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 1/2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, which is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

Contacts

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(
ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Justin Frantz
(
jfrantz@soleburytrout.com )
(617) 221-9100

Russo Partners – Media Relations
Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Release – Motorsport Games to Report First Quarter 2022 Financial Results



Motorsport Games to Report First Quarter 2022 Financial Results

Research, News, and Market Data on Motorsport Games

MIAMI, May 05, 2022 (GLOBE NEWSWIRE) — Motorsport Games, Inc. (NASDAQ: MSGM) (“Motorsport Games”), a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022 after market close. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss the results.

Participants may access the live webcast on the Company’s investor relations website at https://ir.motorsportgames.com under “Events.” The call may also be accessed by dialing 1 (800) 786-6104 from the U.S., or by dialing 1 (416) 981-9029 internationally.

About Motorsport
Games:

Motorsport Games, a Motorsport Network company, combines innovative and engaging video games with exciting esports competitions and content for racing fans and gamers around the globe. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series across PC, PlayStation, Xbox, Nintendo Switch and mobile, including NASCAR, INDYCAR, 24 Hours of Le Mans and the British Touring Car Championship (“BTCC”). Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others.

For more information about Motorsport Games visit: www.motorsportgames.com.

Contacts:
Investors:

Ashley DeSimone
Ashley.DeSimone@icrinc.com

Release – Cypress Development Completes Enertopia Asset Acquisition




Cypress Development Completes Enertopia Asset Acquisition

Research, News, and Market Data on Cypress Development

VANCOUVER, BC, May 5, 2022 /PRNewswire/ – Cypress Development Corp. (TSXV: CYP) (OTCQX: CYDVF) (Frankfurt: C1Z1) (“Cypress” or “the Company”) is pleased to announce that it has completed its acquisition of Enertopia Corporation’s (“Enertopia”) Clayton Valley Lithium Claystone Project (“Enertopia Project”) located adjacent to the Cypress Clayton Valley Lithium Project in Nevada (“Cypress Project”).

“We are pleased with the addition of Enertopia’s property,” commented Dr. Bill Willoughby, President, and CEO of Cypress. “The property is a continuation of the lithium-bearing units in Cypress’ project, with Enertopia’s drilling having shown similar values of lithium. With this consolidation, the data will be incorporated into our resource model and has the potential to enhance the project through our Feasibility Study underway. We expect this consolidation of Clayton Valley lithium claystone projects to be of significant value for both Enertopia and Cypress shareholders.”

The purchase consideration for the Enertopia Project comprised US$1.1 million in cash and the issuance of 3,000,000 common shares in the capital of Cypress (“Consideration Shares”). The transaction also included Enertopia entering into an Irrevocable Proxy and Voting Agreement and Lock-Up Agreement with Cypress in relation to the Consideration Shares. (See Company’s February 24, 2022 new release for further information).  In terms of these agreements, Enertopia inter alia agreed to; (i) vote in favor of shareholder resolutions supported by Cypress’ Board of Directors (ii) certain limitations to the circumstances under which it could sell the Consideration Shares, and (iii) a 12-month standstill in relation to certain corporate activities pertaining to Cypress shares.

In connection with the transaction, the Company has agreed to pay a finder’s fee of US$105,000 to an arm’s-length party, subject to TSX Venture Exchange approval.

About Cypress Development Corp

Cypress Development Corp. is a Canadian based advanced stage lithium company, focused on developing its 100%-owned Clayton Valley Lithium Project in Nevada, USA. Cypress is in the pilot stage of testing on material from its lithium-bearing claystone deposit and progressing towards completing a Feasibility Study and permitting, with the goal of becoming a domestic producer of lithium for the growing electric vehicle and battery storage market.

ON BEHALF OF CYPRESS DEVELOPMENT CORP.

WILLIAM WILLOUGHBY, PhD., PE

President & Chief Executive Officer

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking
Statements

This release includes
certain statements that may be deemed to be “forward-looking
statements”. Forward-looking statements are subject to risks,
uncertainties and assumptions and are identified by words such as 
expects,”
“estimates,” “projects,” “anticipates,”
“believes,” “could,” “scheduled,” and other
similar words. All statements in this release, other than statements of
historical facts, that address events or developments that management of the
Company expects, are forward-looking statements. Although management believes
the expectations expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of future
performance, and actual results or developments may differ materially from
those in the forward-looking statements. The Company undertakes no obligation
to update these forward-looking statements if management’s beliefs, estimates
or opinions, or other factors, should change. Factors that could cause actual
results to differ materially from those in forward-looking statements, include
market prices, exploration, and development successes, continued availability
of capital and financing, and general economic, market or business conditions.
Please see the public filings of the Company at 
www.sedar.com for
further information.

SOURCE Cypress Development Corp.


Release – Allegiant Partner Drills 31 Metres of 456 g/t AgEq Silver Equivalent at Mogollon Property



Allegiant Partner Drills 31 Metres of 456 g/t AgEq Silver Equivalent at Mogollon Property

Research, News, and Market Data on Allegiant Gold

Reno, Nevada /May 5, 2022 –
Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX)
is pleased to announce that Summa Silver Corp. (“Summa”) announced drill results from the first six holes drilled at the Mogollon Property (“Mogollon”) in the State of New Mexico.  Summa is currently working to earn a 75% interest in Mogollon by making share and cash payments totaling US$3 million and spending an additional US$3 million in work commitments. 

According to the May 3, 2022 news release issued by Summa, the following key highlights were reported:

  • 31.0
    metres at 459 grams per tonne silver equivalent*
    (3.88 g/t gold, 129 g/t silver) including 0.5 m at 6,311 g/t silver equivalent (66.8 g/t Au, 638 g/t Ag) and two m at 1,223 g/t silver equivalent (9.32 g/t Au, 431 g/t Ag) in MOG22-05 where total grade thickness through all mineralization is 14,233 g/t AgEq*m;
  • Aggressive step-out: Hole
    MOG22-05
    is a 270-metre step-out from previously reported MOG22-04 which intersected 11.6
    m at 450 g/t silver equivalent
    (2.7 g/t Au, 220 g/t Ag);
  • Open in all directions: The newly drilled mineralized zone at the Consolidated Extension target remains open to expansion in all directions;
  • Aggressive drill plan: The company anticipates a minimum of 25,000 m of drilling in 50 holes is necessary for a spacing of approximately 50 m between holes covering an area of approximately 500 by 300 m to publish its first resource estimate on this first Mogollon property target;
  • Work just beginning: The Consolidated Extension target represents only 1.5 per cent of the total prospective vein and structure length present on the property. All other prospective areas remain largely unexplored;
  • Drilling to resume at Mogollon: The company is planning to resume drilling at Mogollon within 30 days and after the completion of required continuing wildlife surveys;

*Silver equivalent (AgEq) based on an Ag/Au ratio of 85:1 at Mogollon, true widths are unknown.

Full details of the results can be seen in the Summa news release dated May 3, 2022, inclusive of QA/QC procedures.
 

Peter Gianulis, CEO of
Allegiant Gold
, commented: “We are excited about the recent drill results reported by Summa and look forward to the aggressive ongoing drilling program they have outlined at Mogollon, one of the best projects in our portfolio.  Summa has proven to be an excellent partner with strong technical capabilities and qualifications that will prove invaluable in proving up one of the best underground silver/gold projects remaining in the U.S.”
 

ABOUT ALLEGIANT
Allegiant owns 100% of 10 highly-prospective gold projects in the United States, seven of which are located in the mining-friendly jurisdiction of Nevada. Three of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD
Peter Gianulis
CEO

 

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364

ir@allegiantgold.com

Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.

Certain statements and
information contained in this press release constitute “forward-looking
statements” within the meaning of applicable U.S. securities laws and
“forward-looking information” within the meaning of applicable Canadian securities
laws, which are referred to collectively as “forward-looking
statements”. The United States Private Securities Litigation Reform Act of
1995 provides a “safe harbor” for certain forward-looking statements.

Allegiant Gold Ltd.’s
(“Allegiant”) exploration plans for its gold exploration properties, the drill
program at Allegiant’s Eastside project, the preparation and publication of an
updated resource estimate in respect of the Original Zone at the Eastside
project, Allegiant’s future exploration and development plans, including
anticipated costs and timing thereof; Allegiant’s plans for growth through
exploration activities, acquisitions or otherwise; and expectations regarding
future maintenance and capital expenditures, and working capital
requirements.  Forward-looking statements are statements and information
regarding possible events, conditions or results of operations that are based
upon assumptions about future economic conditions and courses of action. All
statements and information other than statements of historical fact may be
forward-looking statements. In some cases, forward-looking statements can be
identified by the use of words such as “seek”, “expect”, “anticipate”,
“budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”,
“predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and
similar words or phrases (including negative variations) suggesting future
outcomes or statements regarding an outlook.  Such forward-looking
statements are based on a number of material factors and assumptions and
involve known and unknown risks, uncertainties and other factors which may
cause actual results, performance or achievements, or industry results, to
differ materially from those anticipated in such forward-looking information. You
are cautioned not to place undue reliance on forward-looking statements
contained in this press release. Some of the known risks and other factors
which could cause actual results to differ materially from those expressed in
the forward-looking statements are described in the sections entitled “Risk
Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed
with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile
at www.sedar.com
Actual results and future events could differ materially from those anticipated
in such statements. Allegiant undertakes no obligation to update or revise any
forward-looking statements included in this press release if these beliefs,
estimates and opinions or other circumstances should change, except as
otherwise required by applicable law.


Release – Element79 Gold Announces $5M Equity Facility Upsized to $10M



Element79 Gold Announces $5M Equity Facility Upsized to $10M

News and Market Data on Element79 Gold

VANCOUVER, BC / ACCESSWIRE
/ May 5, 2022 /
Element79 Gold Corp. (CSE:ELEM)(OTC PINK:ELMGF)(FSE:7YS) (“Element79 Gold”, the “Company”) is pleased to announce that Crescita Capital LLC (“Crescita”) has increased its equity drawdown facility commitment to the Company from $5,000,000 to $10,000,000. The additional funding is being made available pursuant to an amendment dated May 2, 2022 (the “Amendment”) to the original Investment and Advisory Agreement with Crescita dated September 14, 2020 (the “Original Agreement”, and together with the Amendment, the “Agreement”). The Company is able to make drawdown requests for funding, from time to time, pursuant to the facility and on closing of each drawdown, the Company will issue common shares to Crescita in accordance with the terms of the Agreement.

The Company has fully utilized the initial $5,000,000 of Crescita’s invested capital in its corporate development and project advancement since its IPO in August 2021, including completing the Phase 1 exploration program on the Dale property, the drilling program on the Snowbird property, and closing on the acquisition of the Nevada portfolio. Element79 Gold intends to utilize the additional capital to continue progress on its high-tempo development strategy, including the upcoming acquisition of the high-grade Peruvian gold portfolio of Calipuy Resources Inc. (“Calipuy”), the continued advancement of the 43-101 compliant mineral resource at the Company’s flagship Maverick Springs Project, and further exploration of the highly prospective Battle Mountain Portfolio. Near term, additional diamond drilling and metallurgical studies are planned to enable a significant portion of the Maverick Springs resource to be upgraded from the inferred to the indicated category.

“Securing this additional capital, particularly in this market environment where many investors are tightening their purse strings, could not be a stronger vote of confidence for Element79 Gold” remarked James Tworek, CEO of Element79 Gold. “We appreciate Crescita’s repeated investment and belief in our story. The timing is excellent. Element79 Gold now enters into its next phase of development from a position of strength, with the ability to focus on the long-term strategic wins for all our stakeholders.”

In addition to providing for the additional $5,000,000 equity drawdown commitment (the “Second Commitment”), the Amendment provides for certain amendments to the Original Agreement including the addition of the requirement for the Company to make a top up payment to Crescita in the event that the volume weighted average price of the Company’s common shares is less than the subscription price paid by Crescita for a particular drawdown in the 30 days following the drawdown, and amends the fees payable to Crescita for the Second Commitment. The Company will pay an 8% fee to Crescita on the Additional Commitment, which fee will be satisfied by the issuance of 533,333 common shares at a deemed price per share equal to the last closing price of the shares prior to the date of the Amendment, less the maximum discount permitted by the Canadian Securities Exchange. These shares are subject to a four-month hold. A copy of the Original Agreement and Amendment are both filed on SEDAR under the Company’s profile.

Potential Road to
Cashflow Operations: Tailings Utilization and Pre-Production Cashflow

The additional capital will be used to start technical work leading to a PEA and also unlocking the potential for preproduction cashflow through at Machacala as the project develops into 350tpd production. This will also allow the Company to investigate opportunities for cashflow, including reprocessing the historic tailing, estimated to contain approximately 200,000 tonnes at Machacala which were estimated in 1997 by Gold Hawk to contain grades of 1.26 g/t gold and 74 g/t silver.(1) Previous metallurgical studies by Gold Hawk show 87% recoveries of gold and 50%+ recovery of silver in 24 hours of leaching of un-milled tailings, with re-milling able to increase recoveries to 90% of gold and 73% of silver in 24 hours of leaching. While the potential of these tailings is apparent, the Element79 Gold team is reviewing their economic potential and will complete further studies upon completing the acquisition of Calipuy.

“The Peruvian assets, and particularly Machacala, have a clear path towards production in the near-term,” commented Antonios Maragakis. “These funds will be critical in progressing the key geological and engineering work to unlock the mines’ potential in an expedited manner”.

While the potential of these tailings is apparent, the Element79 Gold team is reviewing their economic potential and will complete further studies upon completing the acquisition of Calipuy.

Jason Wells, Managing Director of Crescita Capital stated: “We are excited to continue to financially support Element79 Gold and its transition from an exploration company to a producer. The upside that this brings all of the shareholders is significant”.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Director of Element79 Gold and a “qualified person” as defined by National Instrument 43-101.

About Element79
Gold

Element79 Gold is a mineral exploration company focused on the acquisition, exploration and development of mining properties for gold and associated metals. Element79 Gold has acquired its flagship Maverick Springs Project located in the famous gold mining district of northeastern Nevada, USA, between the Elko and White Pine Counties, where it has recently completed a 43-101-compliant, pit-constrained mineral resource estimate reflecting an Inferred resource of 3.71 million ounces of gold equivalent* “AuEq” at a grade of 0.92 g/t AuEq (0.34 g/t Au and 43.4 g/t Ag)) with an effective date of Feb. 4, 2022. The acquisition of the Maverick Springs Project also included a portfolio of 15 properties along the Battle Mountain trend in Nevada, which the Company is analyzing for further merit of exploration, along with the potential for sale or spin-out. In British Columbia, Element79 Gold has executed a Letter of Intent to acquire a private company which holds the option to 100% interest of the Snowbird High-Grade Gold Project, which consists of 10 mineral claims located in Central British Columbia, approximately 20km west of Fort St. James. In Peru, Element79 Gold has signed a letter of intent to acquire the business and assets of Calipuy Resources Inc., which holds 100% interest in the past-producing Lucero Mine, one of the highest-grade underground mines to be commercially mined in Peru’s history, as well as the past-producing Machacala Mine. The Company also has an option to acquire 100% interest in the Dale Property which consists of 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, Canada in the Timmins Mining Division, Dale Township. For more information about the Company, please visit www.element79.gold or www.element79gold.com.

On Behalf of the Company

James Tworek
CEO

Contact Information

Investor Relations Department

Phone: +1 (604) 200-3608
E-mail: investors@element79.gold

Cautionary Note
Regarding Forward Looking Statements

This press contains “forward?looking information” and “forward-looking statements” under applicable securities laws (collectively, “forward?looking statements”). These statements relate to future events or the Company’s future performance, business prospects or opportunities that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management made in light of management’s experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements include, but are not limited to, statements with respect to: the availability of funding for the Company and issuance of shares to Crescita pursuant to the Agreement; the Company’s plans for use of the funding provided by Crescita; the Company’s plans for exploration and development of the properties the own or are proposing to acquire; the completion of the acquisition of Calipuy and the advancement of its properties; the prospects for mineral resources on certain properties; the prospects for leaching and milling at certain properties; the Company’s business strategy; future planning processes; exploration activities; the timing and result of exploration activities; capital projects and exploration activities and the possible results thereof; acquisition opportunities; and the impact of acquisitions, if any, on the Company. Assumptions may prove to be incorrect and actual results may differ materially from those anticipated, including the risk that the Company does not advance its properties as planned;, that the results of exploration and development are not favorable to the Company; that the projects are not feasible; and the risk that Crescita is not able to fund drawdowns as requested by the Company. Consequently, forward-looking statements cannot be guaranteed. As such, investors are cautioned not to place undue reliance upon forward-looking statements as there can be no assurance that the plans, assumptions or expectations upon which they are placed will occur. All statements other than statements of historical fact may be forward?looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “forecast”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe” and similar expressions) are not statements of historical fact and may be “forward?looking statements”.

Actual results may vary from forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from those expressed or implied by such forward-looking statements, including but not limited to: the duration and effects of the coronavirus and COVID-19; risks related to the integration of acquisitions; actual results of exploration activities; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; commodity prices; variations in ore reserves, grade or recovery rates; actual performance of plant, equipment or processes relative to specifications and expectations; accidents; labour relations; relations with local communities; changes in national or local governments; changes in applicable legislation or application thereof; delays in obtaining approvals or financing or in the completion of development or construction activities; exchange rate fluctuations; requirements for additional capital; government regulation; environmental risks; reclamation expenses; outcomes of pending litigation; limitations on insurance coverage as well as those factors discussed in the Company’s other public disclosure documents, available on www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. The Company believes that the expectations reflected in these forward?looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward?looking statements included herein should not be unduly relied upon. These statements speak only as of the date hereof. The Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.

Sources

  1. Gold Hawk Resources Inc News Release, 2004-06-28

Neither the Canadian
Securities Exchange nor the Market Regulator (as that term is defined in the
policies of the Canadian Securities Exchange) accepts responsibility for the
adequacy or accuracy of this release.

SOURCE: Element79 Gold Corp.


High Food and High Real Estate Prices Should Cause a Shift in Investors’ Watch-Lists


Image Credit: Mark Chinnick


Food Costs, Empty Shelves, and Real Estate Prices Could Provide Investors With Opportunities

Food shortages, inflation, and skyrocketing real estate. These are the most discussed topics among my social media followers. The discussions, and memes, seem to be defining 2022, just as the pandemic defined 2020 and vaccinating for the pandemic defined 2021.  During the two-plus decades I managed billions in funds on Wall Street, my mind became trained to connect dots and look for opportunities. As news stories scrolled down my Bloomberg screen, the automatic thought process was always to ask myself, what’s impacted, is it bullish or bearish, is there an investment opportunity, and what risks might I be missing.

Connecting Dots

Last month I attended my first in-person conference in two years. In the interest of full disclosure, Channelchek is a sponsor of the NobleCon investor conference, but it is without bias that I know this annual event consistently opens my eyes to companies and realities that grow my investment acumen.

During the investor event my mind becomes super busy digesting and connecting economic and investment “dots.” Matching what I know about the markets with what the list of company presenters are explaining about their companies is exciting. Since video replays of the conference presentations are available online, I’ve recently started watching what I did not see in person. In this way, I can make sure I haven’t missed anything.

Working through the companies alphabetically, I started with Alico Inc (ALCO). Alico is a Florida-based food producer and land management company. As mentioned earlier, my social media (and traditional media) newsfeed is full of stories of food inflation, food shortages, and climbing land values, especially in Florida. Alico’s bottom line would seem to benefit from any or all of these situations.

About Alico (ALCO)

The 120-year-old company is one of the largest citrus producers in the U.S., it owns and manages citrus groves in seven Florida counties. Alico is a major landowner with a total of  49,000 prime citrus acres and 84,000 acres in total. In addition to having strong long-term contracts and relationships with companies like Tropicana, the company also holds thousands of acres of ranch land in Florida. As much as 26,000 acres of this real estate is for sale which stands to benefit of shareholders.


Source: Koyfin

The chart above compares the one year performance of ALCO with that of the S&P 500 along with Invesco Dynamic Food & Beverage ETF (PBJ)

During the recorded presentation, Rich Rallo, the chief financial officer of Alico, discussed what he described as a market cap disconnect where the company’s stock price and asset valuation is below the industry norm. This may change as investors allocate away from tech and look for alternatives.

There is plenty to learn from the presentation replay about agri-business in general and Alico specifically. For example, how Alico benefitted from hedging fuel costs, future sales contracts on fruit,  fertilizer, and grove density.

The company recently paid a dividend of about 5%.


Take-Away

Popular investment advice is, “invest in what you know.” It would follow that the more an investor knows, the better equipped they are to recognize opportunities and be comfortable enough to commit capital.

My recent trips to the supermarket has shown me that inflation is running high, and despite the high prices, some shelves are bare. I hear from investors that they want to invest in companies that aren’t hurt by inflation. I suggest they should look for companies that benefit from rising prices.

Alico will be reporting earnings on May 9.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Alico (ALCO) NobleCon18 Presentation Replay



Can Energy Stocks Continue Their High Octane Performance?




Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks



Exposure to Non-Travel Leisure Stocks

 

Stay up to date. Follow us:

 

Science Fiction Becoming Medicines Future


Image Credit: Fantastic Voyage (1966)


Nanoparticles are the Future of Medicine – Researchers are Experimenting with New Ways to Design Tiny Particle Treatments for Cancer

When you hear the word “nanomedicine,” it might call to mind scenarios like those in the 1966 movie “Fantastic Voyage.” The film portrays a medical team shrunken down to ride a microscopic robotic ship through a man’s body to clear a blood clot in his brain.

Nanomedicine has not reached that level of sophistication yet. Although scientists can generate nanomaterials smaller then several nanometers – the “nano” indicating one-billionth of a meter – today’s nanotechnology has not been able to generate functional electronic robotics tiny enough to inject safely into the bloodstream. But since the concept of nanotechnology was first introduced in the 1970s, it has made its mark in many everyday products, including electronics, fabrics, food, water and air treatment processes, cosmetics and drugs. Given these successes across different fields, many medical researchers were eager to use nanotechnology to diagnose and treat disease.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Duxin Sun, Professor of Pharmaceutical Sciences, University of Michigan.

I am a pharmaceutical scientist who was inspired by the promise of nanomedicine. My lab has worked on developing cancer treatments using nanomaterials over the past 20 years. While nanomedicine has seen many successes, some researchers like me have been disappointed by its underwhelming overall performance in cancer. To better translate success in the lab to treatments in the clinic, we proposed a new way to design cancer drugs using nanomaterials. Using this strategy, we developed a treatment that was able to achieve full remission in mice with metastatic breast cancer.

What is Nanomedicine?

Nanomedicine refers to the use of materials at the nanoscale to diagnose and treat disease. Some researchers define nanomedicine as encompassing any medical products using nanomaterials smaller than 1,000 nanometers. Others more narrowly use the term to refer to injectable drugs using nanoparticles smaller than 200 nanometers. Anything larger may not be safe to inject into the bloodstream.

Analysis of the World, from Experts

Several nanomaterials have been successfully used in vaccines. The most well-known examples today are the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. These vaccines used a nanoparticle made of of lipids, or fatty acids, that helps carry the mRNA to where it needs to go in the body to trigger an immune response.

Researchers have also successfully used nanomaterials in diagnostics and medical imaging. Rapid COVID-19 tests and pregnancy tests use gold nanoparticles to form the colored band that designates a positive result. Magnetic resonance imaging, or MRI, often uses nanoparticles as contrast agents that help make an image more visible.

Several nanoparticle-based drugs have been approved for cancer treatment. Doxil (doxorubicin) and Abraxane (paclitaxel) are chemotherapy drugs that use nanomaterials as a delivery mechanism to improve treatment efficacy and reduce side effects.


While nanomedicine isn’t “Fantastic Voyage,” it shares the film’s treatment goal of delivering a drug exactly where it needs to go.

Cancer and Nanomedicine

The potential of nanomedicine to improve a drug’s effectiveness and reduce its toxicity is attractive for cancer researchers working with anti-cancer drugs that often have strong side effects. Indeed, 65% of clinical trials using nanoparticles are focused on cancer.

The idea is that nanoparticle cancer drugs could act like biological missiles that destroy tumors while minimizing damage to healthy organs. Because tumors have leaky blood vessels, researchers believe this would allow nanoparticles to accumulate in tumors. Conversely, because nanoparticles can circulate in the bloodstream longer than traditional cancer treatments, they could accumulate less in healthy organs and reduce toxicity.

Although these design strategies have been successful in mouse models, most nanoparticle cancer drugs have not been shown to be more effective than other cancer drugs. Furthermore, while some nanoparticle-based drugs can reduce toxicity to certain organs, they may increase toxicity in others. For example, while the nanoparticle-based Doxil decreases damage to the heart compared with other chemotherapy options, it can increase the risk of developing hand-foot syndrome.


Improving Nanoparticle-Based Cancer Drugs

To investigate ways to improve how nanoparticle-based cancer drugs are designed, my research team and I examined how well five approved nanoparticle-based cancer drugs accumulate in tumors and avoid healthy cells compared with the same cancer drugs without nanoparticles. Based on the findings of our lab study, we proposed that designing nanoparticles to be more specific to their intended target could improve their translation from animal models to people. This includes creating nanoparticles that address the shortcomings of a particular drug – such as common side effects – and home in on the types of cells they should be targeting in each particular cancer type.

Using these criteria, we designed a nanoparticle-based immunotherapy for metastatic breast cancer. We first identified that breast cancer has a type of immune cell that suppresses immune response, helping the cancer become resistant to treatments that stimulate the immune system to attack tumors. We hypothesized that while drugs could overcome this resistance, they are unable to sufficiently accumulate in these cells to succeed. So we designed nanoparticles made of a common protein called albumin that could deliver cancer drugs directly to where these immune-suppressing cells are located.

When we tested our nanoparticle-based treatment on mice genetically modified to have breast cancer, we were able to eliminate the tumor and achieve complete remission. All of the mice were still alive 200 days after birth. We’re hopeful it will eventually translate from animal models to cancer patients.

Nanomedicine’s Bright but Realistic Future

The success of some drugs that use nanoparticles, such as the COVID-19 mRNA vaccines, has prompted excitement among researchers and the public about their potential use in treating various other diseases, including talks about a future cancer vaccine. However, a vaccine for an infectious disease is not the same as a vaccine for cancer. Cancer vaccines may require different strategies to overcome treatment resistance. Injecting a nanoparticle-based vaccine into the bloodstream also has different design challenges than injecting into muscle.

While the field of nanomedicine has made good progress in getting drugs or diagnostics out of the lab and into the clinic, it still has a long road ahead. Learning from past successes and failures can help researchers develop breakthroughs that allow nanomedicine to live up to its promise.

Suggested Reading



Attacking Tumors by Returning Cancer Cells to the Body



Measuring Cancer Cells to Tailor Treatments





Ocugen (OCGN) NobleCon18 Presentation Replay



Cocrystal Pharma (COCP) NobleCon18 Presentation Replay

 

Stay up to date. Follow us: